Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 7/20 | 0.56 |
| ▸ | PARP10 | Q53GL7 | 3/20 | 0.56 |
| ▸ | PARP11 | Q9NR21 | 3/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | CASP3 | P42574 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4814588 | 0.78 | NPC1 (0.56) | KDM4EALDH1A1GAAHPGDHSD17B10 | |
| SCHEMBL5582807 | 0.76 | NPC1 (0.54) | KDM4EALDH1A1GAAHPGDHSD17B10 | |
| SCHEMBL6922984 | 0.75 | PARP1 (0.58) | PARP1PARP10PARP11ACHE | |
| SCHEMBL4133308 | 0.74 | P2RX7 (0.54) | — | |
| SCHEMBL7581679 | 0.73 | PARP1 (0.56) | PARP1PARP10PARP11ACHE | |
| SCHEMBL27883759 | 0.73 | PARP1 (0.65) | PARP1PARP10PARP11ACHE | |
| SCHEMBL830807 | 0.73 | PARP1 (1.00) | PARP1PARP10PARP11ACHE | |
| SCHEMBL29687894 | 0.73 | PARP1 (1.00) | PARP1PARP10PARP11ACHE | |
| SCHEMBL831538 | 0.73 | PARP1 (1.00) | PARP1PARP10PARP11ACHE | |
| SCHEMBL25452008 | 0.72 | PARP10 (0.51) | PARP1PARP10PARP11ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0355750-B1 | Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process | WARNER LAMBERT CO (US) | 1995-01-25 | — | — | EP | claimed |
| US-5177075-A | Antitumor agents | WARNER-LAMBERT COMPANY (US) | 1993-01-05 | — | — | US | claimed |
| EP-0355750-A1 | Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process | WARNER-LAMBERT COMPANY (US) | 1990-02-28 | — | — | EP | claimed |
| US-6348475-B1 | POLYMERASE INHIBITOR | GUILFORD PHARMACEUTICALS INC. | 2002-02-19 | — | — | US | disclosed |
| US-20020019417-A1 | Methods, compounds and compositions for treating gout | EISAI INC. | 2002-02-14 | — | — | US | disclosed |
| WO-2001091796-A2 | METHODS, COMPOUNDS AND COMPOSITIONS FOR TREATING GOUT | GUILFORD PHARMACEUTICALS INC. (US) | 2001-12-06 | — | — | WO | disclosed |
| EP-0355750-B1 | Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process | WARNER LAMBERT CO (US) | 1995-01-25 | — | — | EP | disclosed |
| US-5177075-A | Antitumor agents | WARNER-LAMBERT COMPANY (US) | 1993-01-05 | — | — | US | disclosed |
| EP-0355750-A1 | Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process | WARNER-LAMBERT COMPANY (US) | 1990-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019417-A1 | Methods, compounds and compositions for treating gout | PARP2, PARP1, PARP3 | PARP1 2/4885PARP10 15/4885PARP11 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.